Ozempic Weight Loss by Week: Full Timeline

Introduction

Ozempic® is semaglutide approved for type 2 diabetes at doses of 0.5, 1.0, and 2.0 mg weekly. Wegovy® is the same molecule approved for chronic weight management at 2.4 mg. The SUSTAIN trial program and parts of the STEP program give the cleanest week-by-week curves for semaglutide weight loss.

SUSTAIN-6 (Marso et al. 2016 NEJM) and SUSTAIN-FORTE (Frias et al. 2021 Lancet) showed semaglutide at 1.0 mg and 2.0 mg producing 5-7% weight loss as a side effect in diabetes patients over 40-56 weeks. STEP 1 (Wilding et al. 2021 NEJM) at 2.4 mg produced 14.9% over 68 weeks in an obesity population.

For most patients prescribed Ozempic for weight loss off-label, the realistic ceiling is 8-12% at one year on 2.0 mg, somewhat below Wegovy’s 14.9% mean. This article walks through the week-by-week curve and what drives the difference.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What’s the Standard Ozempic Dose Ramp?

Ozempic titration starts at 0.25 mg weekly for 4 weeks, then 0.5 mg for at least 4 weeks. From there it can move to 1.0 mg, and (per the 2022 label update) to 2.0 mg. The 2.0 mg dose is the current top.

Quick Answer: Ozempic max dose is 2.0 mg vs Wegovy 2.4 mg; weight loss scales with dose

The 0.25 mg dose is a tolerance dose. It doesn’t produce major appetite suppression for most people but lets the body adjust. The 0.5 mg dose is where appetite changes typically become clearly noticeable.

For weight loss specifically, most clinicians push to 1.0 mg or 2.0 mg as quickly as side effects allow. The diabetes label allows staying at 0.5 mg or 1.0 mg if glycemic control is fine, but for weight outcomes higher doses produce better results.

The ramp typically takes 12-16 weeks to reach 2.0 mg. Slower titration is fine if needed for tolerability.

Weeks 1-4: What Happens on 0.25 Mg?

Mean weight loss in the first 4 weeks is roughly 1-2% of starting body weight. For a 220 lb starting weight, that’s 2-4 lb.

The 0.25 mg dose is mostly a starter. Appetite suppression is mild. Most loss in this window comes from small changes in food intake and reduced water retention as eating patterns shift.

Side effects at 0.25 mg are typically mild. Nausea is the most common, usually peaking in the first week and fading. Constipation and fatigue show up in a smaller share of patients.

If you’re not losing anything by week 4, that’s not a failure. The real dose curve doesn’t start until 0.5 mg and above.

Weeks 5-12: Through the Dose Ramp

By week 12, patients on Ozempic for weight loss typically average 3-5% body weight loss assuming they’ve titrated to 1.0 mg by then. For a 220 lb starting weight, that’s roughly 7-11 lb.

The 0.5 mg and 1.0 mg doses produce meaningful appetite suppression for most patients. Portion sizes drop, snacking decreases, and the calorie deficit becomes clearer.

Each dose increase can trigger 7-10 days of mild GI side effects (nausea, fullness) that then fade. Patients who can’t tolerate an increase often pause at the prior dose for an extra month rather than reverse.

This is the highest-discontinuation window. Most patients who stop Ozempic do so in the first 12 weeks. Pushing through the titration period is the single biggest determinant of long-term results.

Weeks 13-26: Hitting 2.0 Mg

Most patients reach 2.0 mg by week 16-20. By week 26, average cumulative loss on Ozempic at 2.0 mg is around 7-9% body weight, based on extrapolation from SUSTAIN-FORTE.

For a 220 lb starting weight, week 26 lands around 200-205 lb (15-20 lb down). For a 270 lb starting weight, week 26 lands around 245-250 lb (20-25 lb down).

This is where weekly loss rate peaks. The full 2.0 mg dose plus the still-large residual deficit produces the steepest part of the curve. Most patients lose 1-2 lb per week in this window.

Body composition changes become clearly visible. Tape measurements at waist and hips drop. Energy levels usually improve.

Weeks 26-40: Into the Steady Zone

Between weeks 26 and 40, Ozempic patients on 2.0 mg typically move from about 8% to about 10-11% cumulative loss. The slope flattens compared to the dose-ramp phase.

Metabolic adaptation starts. Hunger signals adapt partially. The calorie deficit shrinks because body weight has dropped.

This is the window where many patients first notice slowdowns. A 1 lb per week pace might become 0.5 lb per week. That’s expected, not a failure.

Adding resistance training during this window protects lean mass. Cardio is fine but doesn’t substitute for resistance work. Adequate protein intake (1.2-1.6 g/kg body weight) supports the lean mass preservation.

Weeks 40-52: The One-year Mark

By week 52, mean cumulative loss on Ozempic 2.0 mg is around 11-12% based on SUSTAIN-FORTE extrapolation. This is the practical ceiling for most patients on the diabetes-dose semaglutide.

For comparison, Wegovy at 2.4 mg produced 14% mean loss by week 52 in STEP 1. The 2.0 mg vs 2.4 mg dose difference accounts for roughly 2-3 percentage points of additional loss.

Patients who want more loss past this point usually have three options. First, switch to Wegovy 2.4 mg if appropriate for indication and insurance. Second, switch to tirzepatide (SURMOUNT-5 showed a 6-7 percentage point advantage). Third, focus on lifestyle factors to maximize what 2.0 mg can deliver.

Key Takeaway: SUSTAIN-FORTE (Frias et al. 2021 Lancet) showed 6.9 kg loss at 2.0 mg over 40 weeks in T2D patients

Weeks 52 and Beyond: Maintenance

Past week 52, the curve flattens further. Additional loss in months 13-24 is typically 1-3 percentage points for adherent patients on 2.0 mg.

This is the maintenance zone. Weight typically stabilizes at a defended setpoint determined by dose and lifestyle. Continuing the drug is what holds the loss.

STEP 4 (Rubino et al. 2021 JAMA) showed two-thirds of lost weight returns within a year if semaglutide is stopped. The same biology applies to Ozempic. Long-term use is the path to durable weight outcomes.

If you’re stuck below goal at maintenance dose, the molecule switch to tirzepatide is the most evidence-backed next step. TrimRx offers both compounded semaglutide and compounded tirzepatide, and the free assessment quiz can flag whether switching makes sense for your situation.

How Does Ozempic Compare to Wegovy Week-by-week?

Same molecule (semaglutide), different top doses. Ozempic tops at 2.0 mg, Wegovy at 2.4 mg.

The week-by-week curves run parallel through the ramp phase. The divergence starts at week 13-17 when Wegovy patients reach 2.4 mg and Ozempic patients reach 2.0 mg.

By week 68, Wegovy patients in STEP 1 averaged 14.9% loss. Extrapolated Ozempic 2.0 mg outcomes land closer to 12-13% over the same timeframe.

For patients indicated only for diabetes, Ozempic is the labeled drug. For patients with obesity as the primary indication, Wegovy (or compounded semaglutide titrated to 2.4 mg) tends to produce better weight outcomes.

What If Your Timeline Lags the Trial Curves?

Real-world patients commonly run 2-4 percentage points below trial means at any given week. The drivers are titration delays, missed doses, supply issues, and weaker lifestyle adherence.

If you’re at 4% loss by week 26 instead of 8%, you’re in the lower half but still on a real trajectory. If you’re at 0-1% by week 16 on a stable dose, you’re a likely partial responder.

The 12-week early response check is the cleanest practical test. 5%+ loss by week 12 strongly predicts being in the upper response tier later. Less than 2% by week 12 on appropriate dose suggests partial response.

Talk to your clinician about dose adjustments or molecule changes if early response is weak.

Does Ozempic Plateau Differently Than Wegovy?

The plateau timing is similar because the molecule is the same. Most patients on either drug plateau between months 9-14 on full dose.

The plateau weight differs because the dose differs. Ozempic at 2.0 mg defends a slightly higher weight than Wegovy at 2.4 mg for the same patient.

If you plateau and have headroom on dose, pushing higher is the first move. If you’re already at 2.0 mg, the options are tightening food tracking, adding resistance training, or switching molecules.

Real plateaus are 3+ consecutive weeks with no movement on a stable dose. Anything shorter is normal variation.

Bottom line: SELECT trial (Lincoff et al. 2023 NEJM) added cardiovascular benefit at semaglutide 2.4 mg

FAQ

How Much Weight Will I Lose in the First Month on Ozempic?

Most patients lose 1-2% of body weight in the first 4 weeks at 0.25 mg. For a 220 lb start, that’s 2-4 lb. The bigger loss happens from week 5 onward as the dose increases.

What’s the Average Ozempic Weight Loss at 6 Months?

Approximately 7-9% body weight on 2.0 mg, based on SUSTAIN-FORTE extrapolation. Individual range is wide. Top responders hit 12-15%, partial responders 3-5%.

How Much Weight Can I Lose in One Year on Ozempic?

Around 11-12% mean on 2.0 mg, slightly below Wegovy’s 14.9% at 2.4 mg. Top responders can hit 18-20%. Partial responders stay closer to 5-8%.

Why Is Wegovy More Effective Than Ozempic for Weight Loss?

Higher top dose (2.4 mg vs 2.0 mg). Same molecule, same mechanism, but more drug means stronger appetite suppression and a larger calorie deficit.

Can I Take Ozempic for Weight Loss If I Don’t Have Diabetes?

Off-label, yes, and many clinicians prescribe it that way. The labeled drug for non-diabetic weight management is Wegovy or Zepbound®. Compounded semaglutide titrated to 2.4 mg matches Wegovy’s dosing.

Does Ozempic Stop Working After a Year?

Not in the sense of losing potency. The plateau effect reflects metabolic adaptation, hunger adaptation, and a smaller residual deficit, not drug failure. Continued dosing holds the loss.

Is Compounded Semaglutide as Effective as Ozempic?

The active ingredient is the same. At matched dose from a licensed pharmacy with appropriate storage, the expected weekly curve should match. Compounded versions can be titrated to 2.4 mg or higher under medical supervision.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.